Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN), is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials.

COMMERCIALIZATION

Regen BioPharma identifies 30 promising technologies for rapid commercialization

Narrowed from a review of more than 20,000 US issued patents covering stem cell related matter, Regen BioPharma us in negotiations to license several patents for cell therapy products...

READ MORE

INVESTORS

Investor resources

Regen BioPharma, Inc., is a wholly owned
subsidiary of Bio-Matrix Scientific Group, Inc.
(OTCQB: BMSN) (PINKSHEETS: BMSN). Click
below to access SEC regulatory filings.

READ MORE

LATEST NEWS

Bio-Matrix Scientific Group Recruits RNA Interference Pioneer Dr. David Suhy

SAN DIEGO, CA, Sep 17, 2013 (Marketwired via COMTEX) -- Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) announced that it has recruited, Dr. David Suhy

READ MORE